The Medical Advisor

We are pleased to announce that the first-of-its-kind protocol utilizing Ivermectin, Mebendazole, and Fenbendazole for cancer treatment has been peer-reviewed and officially published on September 19, 2024. Spearheaded by leading researchers like Dr. Ilyes Baghli, Dr. Pierrick Martinez, and the FLCCC’s Dr. Paul Marik, this groundbreaking protocol harnesses the untapped power of Ivermectin, Mebendazole, and Fenbendazole, known for their effectiveness against parasites. Now, these drugs are showing potential to battle cancer, marking the dawn of a new treatment evolution. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondri...

Introduction This article discusses dosage considerations and key factors regarding the use of ivermectin in cancer treatment. Commonly available information about ivermectin dosages is often inaccurate when applied to potential cancer-related uses.  Many sources cite standard dosages recommended by Merck for treating parasitic infections, rather than dosages studied specifically in the context of cancer research. The anti-parasitic dosage is not as effective for people looking for a dosage against cancer. Dosage will need to be adjusted according to the  current weight, the type of Cancer, the stage and grade of the Cancer and the health of the liver. Ivermectin dosage should also be based on ivermectin cancer studies. Multiple factors are considered including studies including ivermectin for cancer, anecdotal studies and case series, the aggressiveness of the cancer type and the cancer stage. It also takes into account the types of medications the person uses. For example, i...

Introduction Access to effective, cancer-specific therapies remains limited, particularly in low- and middle-income countries where cancer survival rates lag behind those in high-income settings due to inadequate funding and infrastructure (9, 10). This has led to increased interest in repurposing existing drugs as more affordable alternatives. Exploring such options may provide valuable insights and potential solutions for expanding treatment accessibility, warranting further scientific investigation. Traditional cancer therapies—including surgery, chemotherapy, radiation, targeted therapy, and immunotherapy—have relatively low documented survival rates and outcomes for advanced, metastatic and stage 4 cancers: Stage 4 Breast Cancer 5-year relative survival rate: 26% (distant/metastatic) (11). Stage 4 Colorectal Cancer 5-year survival rate: 13% (distant) (11). One emerging area of interest in recent years is the potential use of anti-parasitics such as ivermectin and fenbendazole or m...